10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results
10x Genomics (TXG) has announced preliminary, unaudited results for Q4 and full year 2024. The company reported Q4 2024 revenue of ~$165.0 million, showing 9% sequential growth but a 10% year-over-year decrease. Full-year 2024 revenue reached ~$610.8 million, representing a 1% decrease from 2023.
Q4 breakdown shows Instruments revenue at $24.4 million (28% sequential growth, -37% YoY), Consumables revenue at $133.5 million (6% sequential growth, -5% YoY), and Services revenue at $7.1 million (12% sequential growth, +35% YoY). The company's cumulative instrument installations exceeded 7,000 units, including over 5,800 Chromium, 800 Visium, and 400 Xenium instruments. Cash position stood at approximately $393 million as of December 31, 2024.
10x Genomics (TXG) ha annunciato risultati preliminari e non verificati per il Q4 e l'intero anno 2024. L'azienda ha riportato un fatturato del Q4 2024 di circa 165,0 milioni di dollari, mostrando una crescita sequenziale del 9%, ma una diminuzione del 10% rispetto all'anno precedente. Il fatturato dell'intero anno 2024 ha raggiunto circa 610,8 milioni di dollari, rappresentando una diminuzione dell'1% rispetto al 2023.
Il dettaglio del Q4 mostra un fatturato degli Strumenti di 24,4 milioni di dollari (crescita sequenziale del 28%, -37% su base annua), un fatturato dei Consumabili di 133,5 milioni di dollari (crescita sequenziale del 6%, -5% su base annua) e un fatturato dei Servizi di 7,1 milioni di dollari (crescita sequenziale del 12%, +35% su base annua). Le installazioni cumulate di strumenti dell'azienda hanno superato le 7.000 unità, comprese oltre 5.800 unità Chromium, 800 unità Visium e 400 unità Xenium. La posizione di cassa era di circa 393 milioni di dollari al 31 dicembre 2024.
10x Genomics (TXG) ha anunciado resultados preliminares y no auditados para el Q4 y el año completo 2024. La compañía reportó ingresos del Q4 2024 de aproximadamente 165,0 millones de dólares, mostrando un crecimiento secuencial del 9%, pero una disminución del 10% en comparación con el año anterior. Los ingresos del año completo 2024 alcanzaron aproximadamente 610,8 millones de dólares, representando una disminución del 1% con respecto a 2023.
El desglose del Q4 muestra ingresos por Instrumentos de 24,4 millones de dólares (crecimiento secuencial del 28%, -37% interanual), ingresos por Consumibles de 133,5 millones de dólares (crecimiento secuencial del 6%, -5% interanual) e ingresos por Servicios de 7,1 millones de dólares (crecimiento secuencial del 12%, +35% interanual). Las instalaciones acumulativas de instrumentos de la empresa superaron las 7.000 unidades, incluyendo más de 5.800 unidades Chromium, 800 unidades Visium y 400 unidades Xenium. La posición de efectivo era de aproximadamente 393 millones de dólares al 31 de diciembre de 2024.
10x Genomics (TXG)는 2024년 4분기 및 전체 연도에 대한 예비 감사되지 않은 결과를 발표했습니다. 회사는 2024년 4분기 수익 약 1억 6천 5백만 달러를 보고했으며, 이는 전분기 대비 9% 성장했지만 전년 대비 10% 감소한 수치입니다. 2024년 전체 연도 수익은 약 6억 1천 8백만 달러에 달해 2023년 대비 1% 감소했습니다.
4분기 세부사항에 따르면, 기기 수익은 2천 4백 40만 달러(전분기 대비 28% 성장, 전년 대비 -37%), 소모품 수익은 1억 3천 3백 50만 달러(전분기 대비 6% 성장, 전년 대비 -5%), 서비스 수익은 710만 달러(전분기 대비 12% 성장, 전년 대비 +35%)입니다. 회사의 누적 기기 설치 수는 7,000대 이상을 초과하였으며, 이 중 5,800대 이상은 크로뮴, 800대는 비줌, 400대는 제니움 기기입니다. 현금 보유액은 2024년 12월 31일 기준으로 약 3억 9천 3백만 달러에 달했습니다.
10x Genomics (TXG) a annoncé des résultats préliminaires et non vérifiés pour le 4ème trimestre et l'année complète 2024. L'entreprise a rapporté un chiffre d'affaires du 4ème trimestre 2024 d'environ 165,0 millions de dollars, affichant une croissance séquentielle de 9 %, mais une diminution de 10 % par rapport à l'année précédente. Le chiffre d'affaires de l'année entière 2024 a atteint environ 610,8 millions de dollars, représentant une diminution de 1 % par rapport à 2023.
Le détail du 4ème trimestre montre que le chiffre d'affaires des Instruments s'est élevé à 24,4 millions de dollars (croissance séquentielle de 28 %, -37 % sur un an), le chiffre d'affaires des Consommables à 133,5 millions de dollars (croissance séquentielle de 6 %, -5 % sur un an) et le chiffre d'affaires des Services à 7,1 millions de dollars (croissance séquentielle de 12 %, +35 % sur un an). Le nombre cumulative des installations d'instruments de l'entreprise a dépassé les 7 000 unités, y compris plus de 5 800 unités Chromium, 800 unités Visium et 400 unités Xenium. La position de trésorerie était d'environ 393 millions de dollars au 31 décembre 2024.
10x Genomics (TXG) hat vorläufige, ungeprüfte Ergebnisse für das 4. Quartal und das gesamte Jahr 2024 bekannt gegeben. Das Unternehmen berichtete von Umsätzen im 4. Quartal 2024 von etwa 165,0 Millionen Dollar, was einem sequenziellen Wachstum von 9% entspricht, aber einem Rückgang von 10% im Vergleich zum Vorjahreszeitraum. Der Gesamtumsatz für das Jahr 2024 erreichte etwa 610,8 Millionen Dollar, was einem Rückgang von 1% gegenüber 2023 entspricht.
Die Aufschlüsselung für das 4. Quartal zeigt, dass der Umsatz aus den Geräten 24,4 Millionen Dollar betrug (28% sequenzielles Wachstum, -37% im Jahresvergleich), der Umsatz aus Verbrauchsmaterialien 133,5 Millionen Dollar (6% sequenzielles Wachstum, -5% im Jahresvergleich) und der Umsatz aus Dienstleistungen 7,1 Millionen Dollar (12% sequenzielles Wachstum, +35% im Jahresvergleich) betrug. Die kumulierte Anzahl der installierten Geräte des Unternehmens überstieg 7.000 Einheiten, darunter über 5.800 Chromium-, 800 Visium- und 400 Xenium-Geräte. Der Kassenstand belief sich zum 31. Dezember 2024 auf etwa 393 Millionen Dollar.
- 9% sequential revenue growth in Q4 2024
- Services revenue grew 35% YoY in Q4 and 57% for full year
- Strong cash position of $393 million
- Cumulative instrument installations exceeded 7,000 units
- Consumables revenue showed 3% growth over prior year
- 10% YoY revenue decrease in Q4 2024
- 1% overall revenue decline for full year 2024
- 37% YoY decrease in Q4 instruments revenue
- 25% decrease in full-year instruments revenue
- 5% YoY decline in Q4 consumables revenue
Insights
10x Genomics' preliminary Q4 results paint a concerning picture. The 10% year-over-year revenue decline to
The shift in revenue mix is notable - Spatial instruments now generate more revenue than Chromium instruments (
The spatial biology market dynamics revealed in these results warrant attention. Despite overall revenue decline, spatial consumables reached
The sequential growth in Q4 across all categories (instruments
FY 2024 revenue of
Preliminary, Unaudited Select Fourth Quarter 2024 Financial Results
- Revenue of approximately
$165.0 million 9% growth sequentially and a10% decrease as compared to the corresponding prior year period. - Instruments revenue of approximately
$24.4 million 28% growth sequentially and a37% decrease as compared to the corresponding prior year period. Instruments revenue consists of approximately$10.9 million $13.4 million - Consumables revenue of approximately
$133.5 million 6% growth sequentially and a5% decrease as compared to the corresponding prior year period. Consumables revenue consists of approximately$97.7 million $35.8 million - Services revenue of approximately
$7.1 million 12% growth sequentially and35% growth over the corresponding prior year period.
Preliminary, Unaudited Select Full Year 2024 Financial Results
- Revenue of approximately
$610.8 million 1% decrease from the prior year. - Instruments revenue of approximately
$92.7 million 25% decrease from the prior year. Instruments revenue consists of approximately$35.2 million $57.5 million - Consumables revenue of approximately
$493.4 million 3% growth over the prior year. Consumables revenue consists of approximately$372.3 million $121.1 million - Services revenue of approximately
$24.6 million 57% growth over the prior year. - Increased cumulative instruments sold to more than 7,000 instruments as of the end of 2024, which includes over 5,800 Chromium instruments, over 800 Visium instruments and over 400 Xenium instruments.
- Cash, cash equivalents and marketable securities of approximately
$393 million
"Our team delivered solid sequential revenue growth over last quarter," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We are confident the work we've done throughout 2024 sets us up well for the future and better positions us to deliver on the full promise of single cell and spatial biology."
J.P. Morgan Healthcare Conference
10x Genomics, Inc. is providing these updates in advance of its participation in the 43rd Annual J.P. Morgan Healthcare Conference, which begins tomorrow. A live webcast of the company's presentation and question and answer session, which begins at 7:30 a.m. Pacific Time on Monday, January 13, 2025, will be available on the "Investors" section of the company's website at: http://investors.10xgenomics.com. The webcast will be archived and available for replay for at least 30 days after the event.
Preliminary Select Results Subject to Adjustment
10x Genomics, Inc. has not completed preparation of its consolidated financial statements for the fourth quarter or fiscal year of 2024. The select results presented in this news release for the fourth quarter and year ended December 31, 2024 are preliminary and unaudited and are thus inherently uncertain and subject to change as we complete preparation of our consolidated financial statements for the year ended December 31, 2024. 10x Genomics, Inc. is in the process of completing its customary year-end close and review procedures as of and for the fourth quarter and year ended December 31, 2024, and there can be no assurance that final results for these periods will not differ from these estimates. During the course of the preparation of 10x Genomics, Inc.'s consolidated financial statements and related notes as of and for the year ended December 31, 2024, we or our independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary unaudited financial estimates presented herein.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s expected financial results for the fourth quarter and year ended December 31, 2024 and our future opportunities and performance. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information available to management as of the date hereof. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results reflected in the forward-looking statements will be achieved or will occur. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-announces-preliminary-select-fourth-quarter-and-full-year-2024-results-302348608.html
SOURCE 10x Genomics, Inc.
FAQ
What was 10x Genomics (TXG) revenue for Q4 2024?
How much cash does TXG have as of December 31, 2024?
How many instruments has TXG sold cumulatively by the end of 2024?
What was TXG's full-year revenue for 2024?
How did TXG's consumables revenue perform in 2024?
